Humanigen, Inc.
EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS

Last updated:

Abstract:

This invention provides chimeric antigen receptors (CARs) targeting human EphA3 and dual targeting CARs that bind to human EphA3 and to human mutant epidermal growth factor receptor variant III (EGFRvIII). This invention also relates to CAR-T cells comprising the provided CARs or the dual targeting CARs. Methods for treating a solid tumor cancer by administering the CARs are provided.

Status:
Application
Type:

Utility

Filling date:

9 Nov 2020

Issue date:

12 Aug 2021